Reuters logo
BRIEF-MiMedx says FDA approves investigational new drug clinical trial for osteoarthritis of knee
October 17, 2017 / 11:48 AM / a month ago

BRIEF-MiMedx says FDA approves investigational new drug clinical trial for osteoarthritis of knee

Oct 17 (Reuters) - MiMedx Group Inc:

* MiMedx notified by FDA that it can proceed with phase 2B investigational new drug clinical trial for osteoarthritis of the knee

* MiMedx Group Inc - ‍been notified by FDA that its investigational new drug (IND) phase 2B clinical study for osteoarthritis of knee may proceed​

* MiMedx Group Inc - ‍phase 2b trial will enroll approximately 318 patients and company expects patient enrollment to commence in next quarter​

* Mimedx group inc - ‍trial will enroll approximately 318 patients and company expects patient enrollment to commence in next quarter​

* MiMedx Group- clinical trial of phase 2B trial to enroll approximately 318 patients and co expects patient enrollment to commence in next quarter​

* MiMedx group - ‍ believe results of co’s BLA clinical trials for Amniofix injectable and safety profile will demand a price per dose of $1,000 or more​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below